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-43,448 participants
-82.9% White, 9.3% Black, 4.3% Asian
-28% Latinx 
-151 sites
-6 countries (USA, Argentina, Brazil, South Africa, Germany, 
Turkey)
-Randomized to receive either placebo or BNT162b2 mRNA 
COVID vaccine in two intramuscular doses, 21 days apart 
-Primary endpoints: efficacy of BNT162b2 against confirmed 
Covid-19 with onset at least 7 days after the second dose, 
efficacy in participants with and participants without evidence 
of prior infection.




“Appendix 8: Criteria for Allowing Inclusion of Participants With 
Chronic Stable HIV, HCV, or HBV Infection”
-Potential participants with chronic stable HIV, HCV, or HBV 
infection may be considered for inclusion if they fulfill the 
following respective criteria:
• Confirmed stable HIV disease defined as 
1) documented viral load <50 copies/mL 
2) CD4 count >200 cells/mm3 within 6 months before 
enrollment 
3) and on stable antiretroviral therapy for at least 6 months.
-196 PLWH were recruited and included in the trial, but safety 




-79.2% White, 10.2% Black, 4.6% Asian
-20% Latinx 
-Randomized to receive either placebo or mRNA-1273 COVID 
vaccine in two intramuscular doses, 28 days apart 
-Primary endpoints: efficacy of mRNA-1273 in preventing a first 
occurrence of symptomatic COVID-19 with onset at least 14 
days after the second injection
-Secondary endpoints: efficacy of mRNA-1273 against severe 
Covid-19 (RR>30, HR>125, SpO2 <93%, P/F <300mmHg, 
ARDS, SBP <90 mmHg/DBP <60 mmHg, or other clinically 
significant renal, hepatic, or neurologic dysfunction) 


“5.2.11 Immunosuppressive or immunodeficient state, 
asplenia, recurrent severe infections”
- HIV positive participants with CD4 count ≥350 cells/mm3 
and an undetectable HIV viral load within the past year 
- Low level variations from 50-500 viral copies which do not 
lead to changes in antiretroviral therapy [ART] are 
permitted.
- 176 PLWH were recruited for the trial, 90 received vaccine, 
86 received placebo. No COVID-19 cases were noted in 
vaccine group after dose 2, one in placebo 
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Underlying medical conditions that 
increase a person’s risk of severe illness 
from COVID-19
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
Persons with underlying medical 
conditions
- Vaccine may be administered to persons with underlying 
medical conditions who have no contraindications to 
vaccination
- Immediate allergic reaction to COVID-19 vaccine or 
ingredients
- Phase 2/3 clinical trials demonstrate similar safety and 
efficacy profiles in persons with underlying medical 
conditions, including those that place them at increased risk 
for severe COVID-19, compared to persons without 
comorbidities
- Cancer, CKD, COPD, Down Syndrome, CHF, 
Obesity, Pregnancy, T2DM
CDC Recommendations for People with 
Immunodeficiency
“People with HIV and those with weakened immune systems 
due to other illnesses or medication might be at increased risk 
for severe COVID-19. They may receive a COVID-19 vaccine. 
However, they should be aware of the limited safety data:
-Safety of mRNA COVID-19 vaccines for people who have 
weakened immune systems in this group is not yet 
available.
-People living with HIV were included in clinical trials, 
though safety data specific to this group are not yet 
available at this time.
CDC Recommendations for People with 
Immunodeficiency
These individuals may still receive COVID-19 vaccine unless 
otherwise contraindicated
Individuals should be counseled about:
– Unknown vaccine safety and efficacy profiles in 
immunocompromised persons
– Potential for reduced immune responses
– Need to continue to follow all current guidance to protect 
themselves against COVID-19
JCVI and BHIVA Recommendations for 
People with Immunodeficiency
“Priority group 4: Clinically Extremely Vulnerable
-For people with HIV we advise that anybody with a CD4 count 
less than 50 cells/mm3, or who has had an opportunistic illness 
in the last 6 months, should be considered clinically extremely 
vulnerable.
-All people, particularly those with a CD4 count in the range 
50-200 cells/mm3, with additional risk factors should be 
assessed on an individual basis and, if deemed extremely 
clinically vulnerable, can be added to this category. Additional 
risk factors to consider include:
- Detectable viral load
- Low nadir CD4 count
- Additional co-morbidities associated with moderate risk”
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FAQs: 
Question: Can mRNA vaccines give someone COVID-19?
Answer: No. mRNA vaccines do not use the live virus 
that causes COVID-19.
FAQs: 
Question: Can mRNA vaccines interact with our DNA?
Answer: No. 
1) mRNA never enters the nucleus of the cell, which is 
where our DNA (genetic material) is kept. 
2) The cell breaks down and gets rid of the mRNA 
soon after it is finished using the instructions.
FAQs: 
Question: Can we trust such a new vaccine technology?
Answer: Yes. While mRNA vaccines are a novel vaccine 
platform, mRNA vaccines have been studied before for 
flu, Zika, rabies, and cytomegalovirus (CMV). As soon 
as the necessary information about the virus that causes 
COVID-19 was available (January 2020), scientists 
began designing the mRNA instructions for cells to build 
the unique spike protein into an mRNA vaccine.
FAQs: 
Question: Why do I need two shots? 
Answer: Nearly all COVID-19 vaccines being studied in the 
United States require two shots. The first shot starts 
building protection, but everyone has to come back a few 
weeks later for the second one to get the most protection 
the vaccine can offer.
FAQs: 
Question: I’ve already had COVID-19, should I still get the 
vaccine?
Answer: Yes, its not recommended to administer vaccine 
during acute infection, but can be given any time after 
recovery. Natural immunity lasts ~90 days. 
- Long term immunity? 
- Long term side effects?
- Persistent risk of transmission in vaccinated people?
- Vaccine efficacy in patients with varying CD4 levels?
- What percentage of the population needs to be vaccinated 
to achieve herd immunity?
- “When can I get a vaccine?”
Unanswered Questions: 
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How to have effective COVID-19 vaccine 
conversations
1) Start from a place of empathy or understanding
2) Assume patients will want to be vaccinated but may not 
have all of their questions answered
3) Give your strong recommendation
a) “I strongly recommend you get a COVID-19 vaccine 
once it is widely available…”
b) “…This shot is especially important for you because 
of your [job/underlying health condition].”
c) “…I believe in this vaccine so strongly that I plan to 
get it as soon as it is available.”
4) Listen to and respond to questions 
5) Wrapping up the conversation
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